A crystal of a tricyclic compound acting on CRBN protein and a preparation method thereof

By developing a crystallization of a tri-ring compound, the teratogenic and peripheral neuropathy problems of existing CRBN protein modulator drugs have been solved, and stronger immunomodulatory and anti-tumor activity have been achieved, which has improved clinical treatment effect and reduced side effects. .

CN115052874BActive Publication Date: 2024-12-06CHIA TAI TIANQING PHARMA GRP CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202180012797.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-03-06
Filing Date
2021-03-05
Publication Date
2024-12-06
Estimated Expiration
2041-03-05

AI Technical Summary

Technical Problem

The existing CRBN protein modulator drugs have teratogenic effects and peripheral neuropathy side effects, and lack of immunomodulatory and anti-tumor activity, making it difficult to improve clinical treatment effects and reduce side effects.

Method used

Develop a crystallization of a triangular ring compound and its preparation method for preparing drugs for the treatment of CRBN protein-related diseases. Through the analysis of the characteristic peak position and intensity of the X-ray powder diffraction pattern of Cu Kα radiation, a high purity and stability can be prepared. The compound of formula (I) crystallizes A and is prepared by an organic solvent to optimize its crystal characteristics and hygroscopicity.

Benefits of technology

CRBN modulators with no teratogenic effects, fewer peripheral neuropathy, stronger immunomodulation and higher anti-tumor activity were achieved, which improves clinical therapeutic effects and reduces side effects, and has high purity and stable drug properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115052874B_ABST
    Figure CN115052874B_ABST
Patent Text Reader

Abstract

The present application discloses a crystal of a tricyclic compound acting on CRBN protein and a preparation method thereof, specifically relates to a crystal of a compound of formula (I) and a preparation method thereof, and also includes the use of the crystal in the preparation of a drug for treating a disease associated with CRBN protein. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority and benefits of Chinese Patent Application No. 202010153435.5 filed with the State Intellectual Property Office of China on March 6, 2020, and the contents disclosed in said application are incorporated herein by reference in their entirety. Technical Field

[0003] The present application belongs to the field of pharmaceutical chemistry, and relates to a crystal of a tricyclic compound acting on CRBN protein and a method for preparing the same, and specifically to a crystal of a compound of formula (I) and a method for preparing the same, and also includes the use of the crystal in the preparation of drugs for treating diseases related to CRBN protein. Background Art

[0004] Thalidomide, also known as thalidomide, was first synthesized by the German company Grünenthal. From the late 1950s to the early 1960s, it was sold as a sedative in more than 40 countries and was also widely used as an antiemetic for pregnant women. It was eventually withdrawn from the market after tens of thousands of babies were born with phocomelia (morphogenesis disorder).

[0005] Since the "Thalidomide" incident, the teratogenic mechanism of thalidomide has aroused great interest among scientific researchers. It has been confirmed that the protein Cereblon (CRBN) is the target protein of thalidomide's teratogenic effect. Thalidomide forms an E3 ubiquitin ligase complex by binding to CRBN, DNA damage binding protein DDB1 (Damaged DNA Binding Protein 1), CUL4A (Cullin-4A) and Cullins1 regulator (ROC1), which ubiquitinates a variety of substrate proteins to form ubiquitinated chains, so that the substrate proteins are recognized and hydrolyzed by the proteasome. Thalidomide drugs are called immunomodulatory drugs (IMiDs), which activate the E3 ubiquitin ligase complex formed with CRBN to ubiquitinate the transcription factors IKZF1 and IKZF3, which are then recognized and degraded by the proteasome, thereby producing toxic effects on multiple myeloma. The loss of these two transcription factors will stop the growth of myeloma. Currently, amine drugs such as lenalidomide and pomalidomide are the first-line drugs for the treatment of multiple myeloma.

[0006] CRBN is a 442 amino acid protein conserved from plants to humans, located on the p26.3 short arm of human chromosome 3, with a molecular weight of 51 kDa. In humans, the CRBN gene has been identified as a candidate gene for autosomal recessive non-syndromic mild mental retardation (ARNSMR). CRBN is widely expressed in testis, spleen, prostate, liver, pancreas, placenta, kidney, lung, skeletal muscle, ovary, small intestine, peripheral blood leukocytes, colon, brain and retina, and its expression in brain tissue (including retina) and testis is significantly higher than that in other tissues.

[0007] As an important target for anti-tumor and immunomodulator drugs, CRBN has been proven to have clear therapeutic effects in multiple myeloma, chronic lymphocytic leukemia and other hematological malignancies, skin diseases such as erythema nodosum, and autoimmune diseases such as systemic lupus erythematosus. Dosamides have many side effects, especially peripheral neuropathy. At present, there is an urgent need to develop CRBN modulator drugs with no teratogenic effects, less peripheral neuropathy, stronger immunomodulatory effects and higher anti-tumor activity to improve clinical treatment effects, reduce clinical side effects, and facilitate long-term use by patients. SUMMARY OF THE INVENTION

[0009] In one aspect, the present application provides a crystal of a compound of formula (I),

[0010]

[0011] On the other hand, the present application provides a crystalline composition of a compound of formula (I), wherein the crystals of the compound of formula (I) account for more than 50% by weight of the crystalline composition, preferably more than 75%, more preferably more than 90%, and most preferably more than 95%.

[0012] On the other hand, the present application provides a pharmaceutical composition comprising a therapeutically effective amount of a crystal of the compound of formula (I) above, or a crystalline composition of the compound of formula (I) above; the pharmaceutical composition may comprise at least one pharmaceutically acceptable carrier or other excipient.

[0013] On the other hand, the present application provides the use of a crystal of the compound of formula (I), a crystalline composition of the compound of formula (I), or the pharmaceutical composition in the preparation of a drug for treating a disease associated with the CRBN protein.

[0014] On the other hand, the present application provides the use of the crystal of the compound of formula (I), the crystalline composition of the compound of formula (I), or the pharmaceutical composition for treating diseases related to CRBN protein.

[0015] On the other hand, the present application provides a method for treating CRBN protein-related diseases, which comprises administering a therapeutically effective amount of a crystal of the compound of formula (I), a crystalline composition of the compound of formula (I), or the pharmaceutical composition to a mammal in need thereof.

[0016] On the other hand, the present application provides a crystal of the compound of formula (I) for treating CRBN protein-related diseases, a crystalline composition of the compound of formula (I), or the above-mentioned pharmaceutical composition. Summary of the invention

[0017] In one aspect, the present application provides a crystal of a compound of formula (I)

[0018]

[0019] The crystals described in the present application may be in the form of a non-solvate or a solvate, such as a hydrate.

[0020] In one embodiment of the present application, the crystal of the compound of formula (I) is crystal A, which has diffraction peaks at the following 2θ angles in its X-ray powder diffraction pattern using Cu Kα radiation: 10.885±0.200°, 16.433±0.200° and 24.417±0.200°.

[0021] In one embodiment of the present application, the above-mentioned Crystal A has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 10.885±0.200°, 16.433±0.200°, 18.052±0.200°, 18.942±0.200°, 21.124±0.200°, 21.740±0.200°, 24.417±0.200° and 29.034±0.200°.

[0022] In one embodiment of the present application, the above-mentioned Crystal A has a diffraction peak at the following 2θ angles in its X-ray powder diffraction pattern using Cu Kα radiation: 10.885±0.200°, 15.303±0.200°, 16.433±0.200°, 18.052±0.200°, 18.942±0.200°, 21.124±0.200°, 21.740±0.200°, 24.417±0.200°, 25.766±0.200°, 26.189±0.200°, 28.741±0.200° and 29.034±0.200°.

[0023] In one embodiment of the present application, the above-mentioned crystal A has an X-ray powder diffraction pattern using Cu Kα radiation at the following 2θ angles: 10.885±0.200°, 15.303±0.200°, 16.433±0.200°, 18.052±0.200°, 18.942±0.200°, 21.124±0.200°, 21.740±0.200°, 24.417±0.200°, 25.766±0.200°. 0.200°, 26.189±0.200°, 28.741±0.200°, 29.034±0.200°, 31.241±0.200°, 32.588±0.200°, 32.958±0.200°, 33.123±0.200°, 34.985±0.200°, 36.474±0.200° and 37.811±0.200°.

[0024] In some embodiments of the present application, the above-mentioned crystal A has an X-ray powder diffraction pattern using Cu Kα radiation at the following 2θ angles: 10.885°±0.200°, 14.265°±0.200°, 15.303°±0.200°, 15.515°±0.200°, 16.433°±0.200°, 18.052°±0.200°, 18.942°±0.200°, 21.124°±0.200°, 21.740°±0.200°, 23.179°±0.200°, 23.781°±0.200°, 24.417°±0. .200°, 25.766°±0.200°, 26.189°±0.200°, 28.741°±0.200°, 29.034°±0.200°, 31.241°±0.200°, 32.081°±0.200°, 32.588°±0.200°, 32.958°±0.200°, 33.123°±0.200°, 34.985°±0.200°, 36.474°±0.200°, 37.811°±0.200° and 39.622°±0.200°.

[0025] The present application provides a crystalline A of a compound of formula (I), which has an X-ray powder diffraction pattern using Cu Kα radiation, comprising 3, 4, 5, 6, 7 or 8 diffraction peaks selected from the following 2θ angles: 10.885±0.200°, 16.433±0.200°, 18.052±0.200°, 18.942±0.200°, 21.124±0.200°, 21.740±0.200°, 24.417±0.200° and 29.034±0.200°.

[0026] The present application provides a crystalline A of a compound of formula (I), which comprises 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 diffraction peaks selected from the following 2θ angles in its X-ray powder diffraction pattern using Cu Kα radiation: 10.885±0.200°, 15.303±0.200°, 16.433±0.200°, 18.052±0.200°, 18.942±0.200°, 21.124±0.200°, 21.740±0.200°, 24.417±0.200°, 25.766±0.200°, 26.189±0.200°, 28.741±0.200° and 29.034±0.200°.

[0027] The present application provides a crystalline compound A of formula (I), which comprises 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more diffraction peaks selected from the following 2θ angles in its X-ray powder diffraction pattern using Cu Kα radiation: 10.885±0.200°, 15.303±0.200°, 16.433±0.200°, 18.052±0.200°, 18.942±0.200°, 21.124±0.200°, 21.740±0.200°, 24.417±0.200°, 25.890±0.200°, 26.701±0.200°, 27.506±0.200°, 28.513±0.200°, 29.800±0.200°, 30.811±0.200°, 31.5 ±0.200°, 25.766±0.200°, 26.189±0.200°, 28.741±0.200°, 29.034±0.200°, 31.241±0.200°, 32.588±0.200°, 32.958±0.200°, 33.123±0.200°, 34.985±0.200°, 36.474±0.200° and 37.811±0.200°.

[0028] The present application provides a crystalline A of a compound of formula (I), which comprises 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more diffraction peaks selected from the following 2θ angles in an X-ray powder diffraction pattern using Cu Kα radiation: 10.885°±0.200°, 14.265°±0.200°, 15.303°±0.200°, 15.515°±0.200°, 16.433°±0.200°, 18.052°±0.200°, 18.942°±0.200°, 21.124°±0.200°, 21.740°±0.200°, 23.179°±0.200°, 23.781°±0.200°. .200°, 24.417°±0.200°, 25.766°±0.200°, 26.189°±0.200°, 28.741°±0.200°, 29.034°±0.200°, 31.241°±0.200°, 32.081°±0.200°, 32.588°±0.200°, 32.958°±0.200°, 33.123°±0.200°, 34.985°±0.200°, 36.474°±0.200°, 37.811°±0.200° and 39.622°±0.200°.

[0029] In one embodiment of the present application, the peak positions and intensities of characteristic peaks of the X-ray powder diffraction spectrum of the crystal A of the compound of formula (I) using Cu Kα radiation are shown in Table 1:

[0030] Table 1 XRPD spectrum analysis data of compound A of formula (I)

[0031]

[0032] In one embodiment of the present application, the crystal A of the compound of formula (I) has an X-ray powder diffraction pattern using Cu Kα radiation as shown in Figure 1 shown.

[0033] In one embodiment of the present application, the crystalline A of the compound of formula (I) has an endothermic peak at 260.2° C. in its differential scanning calorimetry curve.

[0034] In one embodiment of the present application, the onset position of the absorption peak in the differential scanning calorimetry curve of the crystalline A of the compound of formula (I) is at 256.9°C.

[0035] In one embodiment of the present application, the crystal A of the compound of formula (I) has a differential scanning calorimetry (DSC) spectrum as shown in Figure 2 shown.

[0036] In one embodiment of the present application, the thermogravimetric analysis curve of the crystalline A of the compound of formula (I) shows a weight loss of 0.31% at 120.0°C.

[0037] In one embodiment of the present application, the crystal A of the compound of formula (I) has a thermogravimetric analysis (TGA) measurement graph as shown in Figure 3 shown.

[0038] In one embodiment of the present application, the crystalline A of the compound of formula (I) is prepared in an organic solvent.

[0039] In one embodiment of the present application, the crystalline A of the compound of formula (I) is prepared by precipitation in an organic solvent.

[0040] In one embodiment of the present application, the crystalline A of the compound of formula (I) has a weight gain of less than 0.2% due to moisture absorption at 25° C. and 80% relative humidity.

[0041] On the other hand, the present application provides Crystals A of the compound of formula (I) prepared by using an organic solvent, wherein Crystals A of the compound of formula (I) has the crystal characteristics of the above Crystals A.

[0042] In one embodiment of the present application, the present application provides Crystals A of the compound of formula (I) prepared by precipitation from an organic solvent, wherein Crystals A of the compound of formula (I) has the crystal characteristics of Crystals A described above.

[0043] On the other hand, the present application provides a method for preparing crystal A of a compound of formula (I), the method comprising the step of precipitating the compound of formula (I) from an organic solvent.

[0044] In one embodiment of the present application, the organic solvent is selected from one or more of tetrahydrofuran, dimethyl sulfoxide, acetonitrile, n-heptane, methyl tert-butyl ether, ethyl acetate or isopropanol.

[0045] In a specific embodiment of the present application, the above-mentioned organic solvent is selected from a mixed solvent of tetrahydrofuran and methyl tert-butyl ether.

[0046] In one embodiment of the present application, the preparation of the crystal A of the compound of formula (I) can be carried out under stirring conditions.

[0047] On the other hand, the present application provides a method for preparing crystal A of the compound of formula (I), comprising the step of precipitating the compound of formula (I) in a mixed solvent of a good solvent and a poor solvent.

[0048] In one embodiment of the present application, the present application provides a method for preparing crystal A of compound of formula (I), comprising:

[0049] (a) adding the compound of formula (I) into a good solvent to form a solution of the compound of formula (I);

[0050] (b) slowly adding a poor solvent dropwise under stirring at room temperature;

[0051] (c) Solid precipitates.

[0052] In one embodiment of the present application, the good solvent in the above step (a) is selected from tetrahydrofuran and dimethyl sulfoxide.

[0053] In one embodiment of the present application, the poor solvent in the above step (b) is selected from acetonitrile, n-heptane, methyl tert-butyl ether, ethyl acetate or isopropanol.

[0054] In a specific embodiment of the present application, the good solvent in the above step (a) is selected from tetrahydrofuran, and the poor solvent in the above step (b) is selected from methyl tert-butyl ether.

[0055] In one embodiment of the present application, the mass volume ratio of the compound of formula (I) to the good solvent in the above step (a) is 25-100 mg:1 mL.

[0056] In a specific embodiment of the present application, the mass volume ratio of the compound of formula (I) to the good solvent in the above step (a) is 25 mg:1 mL.

[0057] In one embodiment of the present application, the volume ratio of the good solvent in the above step (a) to the poor solvent in the above step (b) is 1:1-15.

[0058] In a specific embodiment of the present application, the volume ratio of the good solvent in the above step (a) to the poor solvent in the above step (b) is 1:10.

[0059] In one embodiment of the present application, the above step (c) further comprises filtering, centrifuging and drying the precipitated solid.

[0060] On the other hand, the present application also provides a method for preparing crystal A of compound of formula (I), comprising:

[0061] (1) slurrying the compound of formula (I) in an organic solvent;

[0062] (2) Cooling to room temperature, filtering, and concentrating to obtain crystal A of compound of formula (I).

[0063] In one embodiment of the present application, the solvent in the above step (1) is selected from acetonitrile, n-heptane, methyl tert-butyl ether, ethyl acetate or isopropanol.

[0064] On the other hand, the present application also provides a method for preparing crystal A of compound of formula (I), comprising:

[0065] (i) adding the compound of formula (I) into an organic solvent and heating to dissolve;

[0066] (ii) cooling, stirring, and filtering to obtain crystal A of the compound of formula (I).

[0067] In one embodiment of the present application, the organic solvent in the above step (i) is selected from N,N-dimethylformamide (DMF).

[0068] In one embodiment of the present application, the mass volume ratio of the compound of formula (I) to the organic solvent in the above step (i) is 0.1g-1g:1mL, preferably 0.2g-0.5g:1mL, and more preferably 0.2g-0.33g:1mL.

[0069] In one embodiment of the present application, the step (ii) further comprises drying the solid obtained by filtration.

[0070] On the other hand, the present application provides a crystalline composition of a compound of formula (I), wherein the crystals of the compound of formula (I) account for more than 50% by weight of the crystalline composition, preferably more than 75%, more preferably more than 90%, and most preferably more than 95%. The crystalline composition may also contain a small amount of other crystalline or non-crystalline forms of the compound of formula (I).

[0071] On the other hand, the present application provides a pharmaceutical composition comprising a therapeutically effective amount of a crystal of the compound of formula (I) above, or a crystalline composition of the compound of formula (I) above; the pharmaceutical composition may comprise at least one pharmaceutically acceptable carrier or other excipient.

[0072] In one embodiment of the present application, the pharmaceutical composition is selected from pharmaceutical compositions for oral administration, subcutaneous administration, intramuscular administration or intravenous administration.

[0073] In one embodiment of the present application, the pharmaceutical composition is selected from pharmaceutical compositions for oral administration, intramuscular administration or intravenous administration.

[0074] In one embodiment of the present application, the pharmaceutical composition is selected from pharmaceutical compositions for oral administration.

[0075] On the other hand, the present application provides an oral pharmaceutical composition, which comprises a therapeutically effective amount of a crystal of the compound of formula (I) above, or a crystalline composition of the compound of formula (I) above; the pharmaceutical composition may comprise at least one pharmaceutically acceptable carrier or other excipient.

[0076] In one embodiment of the present application, the pharmaceutical composition is selected from tablets, capsules, granules, powders, pills, powders, lozenges, syrups or suspensions.

[0077] In one embodiment of the present application, the pharmaceutical composition is selected from tablets, capsules or granules.

[0078] In one embodiment of the present application, the pharmaceutical composition is selected from aqueous or non-aqueous injection solutions.

[0079] In one embodiment of the present application, the pharmaceutical composition is selected from a rapid-release, delayed-release or modified-release pharmaceutical composition.

[0080] In one embodiment of the present application, the pharmaceutical composition is selected from a rapid-release pharmaceutical composition.

[0081] In one embodiment of the present application, the pharmaceutical composition is selected from a rapid-release oral pharmaceutical composition.

[0082] On the other hand, the present application provides the use of a crystal of the compound of formula (I), a crystalline composition of the compound of formula (I), or the pharmaceutical composition in the preparation of a drug for treating a disease associated with the CRBN protein.

[0083] On the other hand, the present application provides the use of the crystal of the compound of formula (I), the crystalline composition of the compound of formula (I), or the pharmaceutical composition for treating diseases related to CRBN protein.

[0084] On the other hand, the present application provides a method for treating CRBN protein-related diseases, which comprises administering a therapeutically effective amount of a crystal of the compound of formula (I), a crystalline composition of the compound of formula (I), or the pharmaceutical composition to a mammal in need thereof.

[0085] On the other hand, the present application provides a crystal of the compound of formula (I) for treating CRBN protein-related diseases, a crystalline composition of the compound of formula (I), or the above-mentioned pharmaceutical composition.

[0086] In one embodiment of the present application, the mammal is a human.

[0087] In one embodiment of the present application, the disease associated with CRBN protein is selected from multiple myeloma.

[0088] On the other hand, the present application also provides a crystal of a compound of formula (I) having a moisture absorption weight gain ΔW% of less than 0.2% at 25° C. and 80% RH, wherein the crystal is crystal A of the compound of formula (I).

[0089] The crystals of the compound of formula (I) described in the present application are stable in nature, low in hygroscopicity, and have good prospects for drug development. The crystals of the compound of formula (I) described in the present application also have excellent cell proliferation inhibition, significant tumor inhibition and tumor shrinkage effects, and high oral bioavailability.

[0090] In the present application, the pharmaceutical composition can be prepared into a certain dosage form for administration, preferably oral administration, parenteral administration (including subcutaneous, intramuscular and intravenous), rectal administration, etc. For example, dosage forms suitable for oral administration include tablets, capsules, granules, powders, pills, powders, lozenges, syrups or suspensions; dosage forms suitable for parenteral administration include aqueous or non-aqueous injection solutions or emulsions; dosage forms suitable for rectal administration include suppositories using hydrophilic or hydrophobic carriers. As needed, the above dosage forms can also be prepared into dosage forms suitable for rapid release, delayed release or regulated release of the active ingredient.

[0091] In this application, the X-ray powder diffraction spectrum of the sample was measured under the following conditions: instrument: Bruker D8ADVANCE X-ray diffractometer; target: Cu:Kα; wavelength 2θ angle range: 3-40°; scattering slit: 0.60mm; detector slit: 10.50mm; anti-scattering slit: 7.10mm; scanning rate: 10deg / min; sample rotation speed: 15rpm; Cu target tube voltage and tube current: 40KV, 40mA.

[0092] In the present application, the DSC spectrum is measured under the following conditions: instrument: TA Q2000 differential scanning calorimeter; temperature range: 30-320°C; heating rate: 10°C / min.

[0093] In the present application, TGA thermogravimetric analysis is measured under the following conditions: instrument: DISCOVERY TGA 5500 thermogravimetric analyzer; temperature range: 25-300°C; heating rate: 10°C / min.

[0094] In the present application, dynamic vapor sorption analysis (Dynamic Vapor Sorption, DVS) is measured under the following conditions: instrument: SMS DVS Advantage-1 dynamic vapor sorption instrument; equilibrium: dm / dt=0.01% / min (shortest: 60min, longest: 180min); drying: drying at 0%RH for 120min; RH(%) test step: 10%; RH(%) test step range: 0%-90%-0%.

[0095] It should be noted that in the powder X-ray diffraction spectrum, the position of the peak or the relative intensity of the peak may vary due to factors such as the measuring instrument, measuring method / conditions, etc. For any specific crystal form, there may be an error in the position of the peak, and the measurement error of the 2θ value is ±0.2°. Therefore, when determining each crystal form, this error should be taken into account, and the error is also within the scope of this application.

[0096] It should be noted that for the same crystal form, the position of the endothermic peak of DSC may be different due to factors such as the measuring instrument, measuring method / conditions, etc. For any specific crystal form, the position of the endothermic peak may have an error, which may be ±5°C, ±3°C, or ±2°C. Therefore, when determining each crystal form, this error should be taken into account, and the error is also within the scope of this application.

[0097] It should be noted that for the same crystal form, the position of the weight loss temperature of TGA may be different due to factors such as the measuring instrument, measuring method / conditions, etc. For any specific crystal form, the position of the weight loss temperature may have an error, which may be ±5°C, ±3°C, or ±2°C. Therefore, when determining each crystal form, this error should be taken into account, and the error is also within the scope of this application.

[0098] Definition and Description

[0099] Unless otherwise specified, the following terms and phrases used herein are intended to have the following meanings. A particular phrase or term should not be considered to be uncertain or unclear in the absence of a special definition, but should be understood according to its ordinary meaning. When a trade name appears in this article, it is intended to refer to its corresponding commercial product or its active ingredient.

[0100] "Mammal" includes humans and domestic animals such as laboratory mammals and household pets (e.g., cats, dogs, pigs, sheep, cattle, goats, horses, rabbits), and non-domesticated mammals, such as wild mammals, etc.

[0101] The term "pharmaceutical composition" refers to a preparation of the present invention compound and a medium generally accepted in the art for delivering biologically active compounds to mammals, such as humans. The medium includes all pharmaceutically acceptable carriers for its use. The pharmaceutical composition facilitates the administration of the compound to an organism.

[0102] The term "therapeutically effective amount" refers to a sufficient amount of a drug or pharmaceutical agent that is non-toxic but can achieve the desired effect. The determination of the effective amount varies from person to person, depending on the age and general condition of the recipient, and also on the specific active substance. The appropriate effective amount in each case can be determined by a person skilled in the art based on routine experiments.

[0103] The term "treatment" means administering the compound or formulation described herein to improve or eliminate a disease or one or more symptoms associated with the disease, and includes:

[0104] (i) inhibiting a disease or disease state, i.e. arresting its development;

[0105] (ii) ameliorating a disease or condition, even if causing regression of the disease or condition.

[0106] In the present application, "pharmaceutically acceptable carrier" refers to those carriers that are administered together with the active ingredient, have no significant irritation to the organism, and do not impair the biological activity and performance of the active compound. For other information about the carrier, reference may be made to Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005), the contents of which are incorporated herein by reference.

[0107] In the present application, "room temperature" refers to 20°C to 30°C.

[0108] The word "comprise" or "comprises" and its English variations such as comprises or comprising should be construed in an open and non-exclusive sense, ie, "including but not limited to". BRIEF DESCRIPTION OF THE DRAWINGS

[0109] Figure 1 It is the X-ray powder diffraction (XRPD) pattern of crystalline A of the compound of formula (I).

[0110] Figure 2 The differential scanning calorimetry (DSC) diagram of the crystal A of the compound of formula (I) is shown in FIG.

[0111] Figure 3 This is the thermogravimetric analysis (TGA) diagram of crystal A of compound of formula (I).

[0112] Figure 4 This is a dynamic vapor sorption analysis (DVS) diagram of crystal A of compound of formula (I).

[0113] Figure 5 The figure is a graph showing the changes in intracellular IKZF3 protein levels detected by WB after treating multiple myeloma cells MM.1S with the compound of formula (I) at concentrations of 50 and 500 nM.

[0114] Note: Negative Control stands for negative control. DETAILED DESCRIPTION

[0115] In order to better understand the content of this application, further description is given below in conjunction with specific embodiments, but the specific implementation methods are not limitations on the content of this application.

[0116] Example 1: Preparation of the compound of formula (I)

[0117]

[0118] Step 1: Synthesis of intermediate 2

[0119] At room temperature, compound 1 (25.00 g, 183.62 mmol) was dissolved in a mixed solution of diethyl carbonate (250 mL) and toluene (250 mL), the reaction solution was cooled to 0°C, sodium hydrogen (36.72 g, 918.12 mmol, purity: 60%) was added in batches, the reaction mixture was heated to 120°C and stirred for 12 hours. After the reaction was completed, it was cooled to room temperature, the reaction solution was slowly poured into ice water (500 mL), extracted with ethyl acetate (500 mL×2), the organic phase was discarded, the aqueous phase was adjusted to pH=3 with 3N hydrochloric acid, and extracted with ethyl acetate (1 L×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent to obtain intermediate 2. 1 H NMR (400MHz, DMSO_d6) δ: 12.52 (s, 1H), 7.82 (dd, J=1.6, 7.6Hz, 1H), 7.68-7.62 (m, 1H), 7.40-7.32 (m, 2H), 5.59 (s, 1H).

[0120] Step 2: Synthesis of intermediate 3

[0121] At room temperature, intermediate 2 (25.00 g, 154.19 mmol) was dissolved in methanol (300 mL), and sodium acetate (44.27 g, 539.65 mmol) and hydroxylamine hydrochloride (37.50 g, 539.65 mmol) were added in sequence. The reaction mixture was stirred at 15 ° C for 1.5 hours, then heated to 80 ° C and stirred for 12 hours. After the reaction was completed, it was cooled to room temperature, the reaction solution was adjusted to pH = 5 with 3N hydrochloric acid, and then concentrated under reduced pressure to remove the solvent. Water (200 mL) was added, and the reaction bottle was placed in an ice water bath to cool, and 3N hydrochloric acid was used to adjust the pH to 3. After the mixture was stirred for 30 minutes, it was filtered, the filter cake was collected and concentrated under reduced pressure to remove the solvent. Intermediate 3 was obtained.

[0122] Step 3: Synthesis of intermediate 4

[0123] At room temperature, intermediate 3 (28.00 g, 158.05 mmol) was dissolved in ethanol (600 mL), and concentrated sulfuric acid (28 mL, purity: 98%) was added. The reaction mixture was heated to 90°C and stirred for 6 hours. After the reaction was completed, it was cooled to room temperature, concentrated under reduced pressure to remove the solvent, and the residue was diluted with ethyl acetate (300 mL) and water (300 mL) and then adjusted to pH = 7 by adding solid sodium bicarbonate. After separation, the organic phase was collected, and the aqueous phase was extracted with ethyl acetate (300 mL × 2). The organic phases were combined, washed with saturated brine (300 mL) in turn, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0-0 / 1, volume ratio) to obtain intermediate 4. 1 H NMR (400MHz, DMSO_d6) δ: 7.84 (d, J=8.0Hz, 1H), 7.74 (d, J=8.4Hz, 1H), 7.70-7.63 (m , 1H), 7.44-7.37 (m, 1H), 4.21 (s, 2H), 4.14 (q, J=7.2Hz, 2H), 1.19 (t, J=7.2Hz, 3H).

[0124] Step 4: Synthesis of intermediate 5

[0125] At 0°C, add intermediate 4 (24.00 g, 116.95 mmol) to fuming nitric acid (180 mL), and stir the reaction mixture at 0°C for 2 hours. After the reaction is completed, pour the reaction solution into ice water (500 mL) and extract with ethyl acetate (500 mL×3). Combine the organic phases, wash with water (200 mL×2) in turn, dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to remove the solvent. The resulting residue is separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0-10 / 1, volume ratio) to obtain intermediate 5. 1 H NMR (400MHz, DMSO_d6) δ: 8.93 (d, J=2.4Hz, 1H), 8.51 (dd, J=2.0, 9.2Hz, 1H), 7 .99 (d, J=9.2Hz, 1H), 4.34 (s, 2H), 4.15 (q, J=7.4Hz, 2H), 1.2 (t, J=7.0Hz, 3H).

[0126] Step 5: Synthesis of intermediate 6

[0127] At room temperature, intermediate 5 (5.50 g, 21.98 mmol) was dissolved in ethanol (120 mL), tin chloride dihydrate (19.84 g, 87.93 mmol) was added, and the reaction mixture was stirred at 15 ° C for 2 hours. Tin chloride dihydrate (14.88 g, 65.95 mmol) was added and the reaction was continued for 5 hours. After the reaction was completed, the solvent was removed by concentration under reduced pressure, and the residue was diluted with dichloromethane (200 mL) and water (300 mL) and then adjusted to pH = 7 by adding solid sodium bicarbonate. The resulting solution was filtered through a funnel filled with diatomaceous earth, and the diatomaceous earth was rinsed with 2-methyltetrahydrofuran (1000 mL). The filtrate was collected, and the organic phase was collected after separation. The aqueous phase was extracted with 2-methyltetrahydrofuran (200 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The obtained residue was separated by column chromatography (neutral alumina column 200-300 mesh, eluent: petroleum ether / ethyl acetate / dichloromethane = 1 / 0 / 0-6 / 3 / 1, volume ratio) to obtain intermediate 6.

[0128] Step 6: Synthesis of intermediate 7

[0129] At room temperature, intermediate 6 (1.50 g, 6.81 mmol) was dissolved in dichloromethane (30 mL), N-bromosuccinimide (1.21 g, 6.81 mmol) was added at 0°C, and the reaction mixture was stirred at 0-15°C for 2 hours. After the reaction was completed, water (15 mL) was added to the reaction solution, and it was extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL) in turn, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. Intermediate 7 was obtained. 1 H NMR (400MHz, DMSO_d6) δ: 7.51 (d, J=8.8Hz, 1H), 7.16 (d, J=8.8Hz, 1H), 5.42 (s, 2H), 4.20-4.08 (m, 4H), 1.20 (t, J=7.0Hz, 3H).

[0130] Step 7: Synthesis of Intermediate 8

[0131] At room temperature and under nitrogen protection, the intermediate 7 (1.1 g, 3.68 mmol) was dissolved in N, N-dimethylformamide (10 mL), trimethylsilyl acetylene (722.38 mg, 7.36 mmol), triethylamine (930.30 mg, 9.20 mmol), potassium iodide (610.46 mg, 3.68 mmol), cuprous iodide (70.04 mg, 368.00 μmol), [1,1-bis(triphenylphosphino)ferrocene] dichloropalladium dichloromethane (300.31 mg, 368.00 μmol) were added, and the reaction mixture was heated to 110 ° C. and microwaved (3 bar) for 3 hours. After the reaction was completed, it was cooled to room temperature, water (30 mL) was added, and it was extracted with ethyl acetate (30 mL×3). The organic phases were combined, washed with half-saturated brine (20 mL) in turn, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The obtained residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1, volume ratio) and separated by preparative HPLC (mobile phase: acetonitrile / water; acidic system: 0.05% HCl) to obtain Intermediate 8. 1 H NMR (400MHz, DMSO_d6) δ: 11.63 (s, 1H), 7.69 (d, J=9.2Hz, 1H), 7.42 (d, J=9.2Hz, 1H), 6.79 (d, J=1.2Hz, 1H), 4.26 (s, 2H), 4.15 (q, J=7.0Hz, 2H), 1.20 (t, J=7.0Hz, 3H), 0.34 (s, 9H).

[0132] Step 8: Synthesis of Intermediate 9

[0133] At room temperature, intermediate 8 (300.00 mg, 948.09 μmol) was dissolved in acetonitrile (20 mL), and a tetrahydrofuran solution of tetrabutylammonium fluoride (1 M, 948.09 μL) was added. The reaction mixture was heated to 70°C and stirred for 2 hours. After the reaction was completed, the mixture was cooled to room temperature and concentrated under reduced pressure to remove the solvent. The resulting residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0-2 / 1, volume ratio) to obtain intermediate 9. 1 H NMR (400MHz, DMSO_d6) δ: 11.69 (s, 1H), 7.71 (d, J=8.8Hz, 1H), 7.55 (t, J=2.8Hz, 1H), 7.42 (d, J=8.8Hz, 1H), 6.63 (s, 1H), 4.26 (s, 2H), 4.14 (q, J=7.2Hz, 2H), 1.17 (t, J=7.0Hz, 3H).

[0134] Step 9: Synthesis of compound of formula (I)

[0135] At 0°C, the intermediate 9 (125.00 mg, 511.78 μmol) was dissolved in tetrahydrofuran (7 mL), and acrylamide (36.38 mg, 511.78 μmol) and potassium tert-butoxide (57.43 mg, 511.78 μmol) were added in sequence. The reaction mixture was returned to room temperature (10°C) and stirred for reaction for 1 hour. After the reaction was completed, water (10 mL) was added to the reaction solution, and extracted with 2-methyltetrahydrofuran (20 mL×3). The organic phases were combined, washed with saturated brine (10 mL) in sequence, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The obtained residue was separated by preparative HPLC (mobile phase: acetonitrile / water; acidic system: 0.05% HCl) to obtain the target compound of formula (I). MS-ESI m / z.: 270.1 [M+H] + .; 1 H NMR (400MHz, DMSO_d6) δ: 11.71 (s, 1H), 11.20 (s, 1H), 7.72 (d, J = 8.8Hz, 1H), 7.56 (t, J = 2.6Hz, 1H), 7.44 (d, J = 9.2Hz, 1H) , 6.56 (s, 1H), 4.69 (dd, J=5.0, 11.8Hz, 1H), 2.90-2.81 (m, 1H), 2.70-2.59 (m, 1H), 2.47-2.37 (m, 1H), 2.28-2.15 (m, 1H).

[0136] Example 2: Preparation of Crystalline Compound A of Formula (I)

[0137] 50 mg of the compound of formula (I) was weighed and added to a glass bottle, 2 mL of tetrahydrofuran was added at room temperature to form a tetrahydrofuran solution of the compound of formula (I), and 20 mL of methyl tert-butyl ether was slowly added dropwise under stirring at room temperature, solids precipitated, and centrifuged and filtered. The obtained solid was placed in a vacuum drying oven at 30° C. and dried for 2 hours to obtain a crystal A of the compound of formula (I).

[0138] Example 3: Preparation of Crystalline Compound A of Formula (I)

[0139] Weigh 2 g of the compound of formula (I), add 6 mL of DMF, raise the temperature to 85-90° C., then naturally cool to room temperature, stir for 36 hours, filter, rinse the filter cake with 6 mL of n-heptane, and vacuum dry at 40-45° C. for 5 hours to obtain crystals A of the compound of formula (I).

[0140] Experimental Example 1: Study on the Hygroscopicity of Crystal A of Compound of Formula (I)

[0141] Hygroscopicity classification ΔW% deliquescence Absorbs enough water to form a liquid Highly hygroscopic ΔW%≥15% Hygroscopic 15%>ΔW%≥2% Slightly hygroscopic 2%>ΔW%≥0.2% No or almost no hygroscopicity ΔW%<0.2%

[0142] Note: ΔW% indicates the weight gain of the test sample at 25±1℃ and 80±2%RH.

[0143] Experimental instruments:

[0144] SMS DVS Advantage-1 Dynamic Vapor Sorption Tester

[0145] Experimental methods:

[0146] 10-15 mg of crystal A of the compound of formula (I) was placed in a DVS sample tray for testing.

[0147] Experimental results:

[0148] The DVS spectrum of the crystal A of the compound of formula (I) is as follows Figure 4 As shown, ΔW = 0.13%.

[0149] Experimental conclusion:

[0150] The weight gain of the crystal A of the compound of formula (I) at 25° C. and 80% RH is 0.13%, which is less than 0.2%, with no or almost no hygroscopicity, and its crystal form remains unchanged.

[0151] Experimental Example 2: Stability test of crystal A of compound of formula (I) in different solvents

[0152] Weigh about 50 mg of each crystal A of the compound of formula (I), add them to different 2.0 mL glass vials, and add appropriate amounts of single or mixed solvents in the table below. After adding the magnet, place the above sample on a magnetic stirrer (25°C / 50°C, 700 rpm) for stirring (protect from light). Stir the sample at 25°C for 1 week, centrifuge and place the obtained solid sample in a 40°C vacuum drying oven to dry overnight. Stir the sample at 50°C for 2 days, centrifuge it in a centrifuge tube with a filter membrane, discard the solvent below, place it in a fume hood for 1 hour, and let it dry naturally. The obtained dried sample was subjected to XRPD to detect its crystalline state. The results are shown in Table 2.

[0153] Table 2 Stability test of compound A of formula (I) in different solvents

[0154]

[0155] Experimental conclusion: Crystalline A of compound of formula (I) has good stability in solvents such as methanol, ethanol, acetone, acetonitrile, tetrahydrofuran, methyl tert-butyl ether, ethyl acetate, water, and a mixed solvent of acetonitrile or acetone and water.

[0156] Experimental Example 3: Solid Stability Test of Compound Crystal A of Formula (I) under High Temperature, High Humidity and Strong Light Conditions

[0157] According to the "Guidelines for Stability Testing of APIs and Preparations" (Chinese Pharmacopoeia 2020 Edition Part IV General Rules 9001), the stability of the crystals of compound A of formula (I) was investigated under high temperature (60°C, open), high humidity (room temperature / relative humidity 92.5%, open) and strong light (5000±500Lux, 90μw / cm 2 , stability under open) conditions.

[0158] Weigh 1.5 g of the crystal A of the compound of formula (I), put it into an open weighing bottle, and spread it into a thin layer. The samples placed under high temperature conditions were placed in an electric heating blast drying oven for inspection, and the samples placed under high humidity conditions were placed in a comprehensive drug stability test box for inspection. Samples were taken for inspection on the 5th, 10th and 30th days, and the test results were compared with the initial test results on day 0; the samples placed under strong light conditions were placed open, and samples were taken for inspection on the 5th and 10th days, and the test results were compared with the initial test results on day 0. The experimental results are shown in Table 3 below.

[0159] Table 3 Solid stability test results of compound A of formula (I) under high temperature, high humidity and strong light conditions

[0160]

[0161] Conclusion: Crystal A of compound of formula (I) has good stability under high temperature, high humidity or strong light conditions.

[0162] Experimental Example 4: Solid stability experiment of crystal A of compound of formula (I) under accelerated conditions According to the "Guidelines for Stability Testing of APIs and Preparations" (Chinese Pharmacopoeia 2020 Edition, Part IV, General Rules 9001), the stability of crystal A of compound of formula (I) under accelerated conditions of high temperature and high humidity (40°C / relative humidity 75%, sealed) was investigated.

[0163] About 1.5 g of the crystals A of the compound of formula (I) were weighed and placed in a double-layer low-density polyethylene bag. Each layer of the low-density polyethylene bag was sealed with buckles, and then placed in an aluminum foil bag. Samples were taken for testing in the first, second, third and sixth months, and the test results were compared with the initial test results on day 0. This experiment was repeated twice, each time using a different batch of crystals A of the compound of formula (I). The experimental results are shown in Table 4 below.

[0164] Table 4 Solid stability test results of compound A of formula (I) under accelerated conditions (40°C / relative humidity 75%, sealed)

[0165]

[0166] Conclusion: Crystalline A of compound of formula (I) has good stability under accelerated conditions of 40°C / 75% relative humidity.

[0167] Experimental Example 5: Solid Stability Test of Crystalline Compound A of Formula (I) under Long-term Conditions

[0168] According to the "Guidelines for Stability Testing of APIs and Preparations" (Chinese Pharmacopoeia 2020 Edition Part IV General Rules 9001), the stability of crystals A of compound of formula (I) under long-term conditions (25°C / relative humidity 60%, sealed) was investigated.

[0169] About 1.5 g of the crystals A of the compound of formula (I) were weighed and placed in a double-layer low-density polyethylene bag. Each layer of the low-density polyethylene bag was sealed with buckles, and then placed in an aluminum foil bag. Samples were taken for testing at the 3rd and 6th months, and the test results were compared with the initial test results at day 0. This experiment was repeated twice, each time using a different batch of crystals A of the compound of formula (I). The experimental results are shown in Table 5 below.

[0170] Table 5 Solid stability test results of the compound of formula (I) crystal A under long-term conditions (25°C / relative humidity 60%, sealed)

[0171]

[0172] Conclusion: Crystalline A of compound of formula (I) has good stability under long-term conditions of 25°C / relative humidity 60%.

[0173] Test Example 1: In vitro testing of IKZF3 protein levels in multiple myeloma cells

[0174] Purpose:

[0175] The WB method was used to study the regulation of the IKZF3 protein level in multiple myeloma cells MM.1S by the compound of formula (I) at different concentrations.

[0176] Experimental protocol:

[0177] 1) Thaw MM.1S cells and passage them twice;

[0178] 2) MM.1S cells were cultured at 1×10 6 The cells were seeded in 6-well plates and then treated with a certain concentration of the compound of formula (I);

[0179] 3) After 16 hours of treatment, the cultured cell samples were dissolved in RIPA buffer (Sigma-Aldrich) or NETN buffer (150 mM NaCl, 1% NP-40, 50 mM Tris-HCl, pH = 8.0) with a complete set of protease inhibitors (Roche) on ice and allowed to stand for 20 minutes;

[0180] 4) After centrifugation (speed: 17950 rpm) for 15 min, the supernatant was collected and subjected to protein quantification test (Pierce BCA protein assay kit, Thermo);

[0181] 5) Equal amounts of 20 μg of protein were separated by SDS-PAGE and transferred to PVDF or nylon membranes (Invitrogen);

[0182] 6) Add 5% skim milk powder, and then incubate in 5% BSA with primary antibodies (anti-IKZF3 (NBP2-24495, Novus Biologicals) and anti-Actin (1844-1, Epitomics)) at 4°C overnight;

[0183] 7) After reacting with HRP-linked secondary antibody (Goat-anti-rabbit IgG (sc-2004, Santa Cruz)) for 1 hour, the bands on the membrane were detected using a chemiluminescent substrate (Thermo Scientific).

[0184] The experimental results are as follows Figure 5 shown.

[0185] Test Example 2: Evaluation of antiproliferative effects in multiple myeloma cell lines MM.1S and NCI-H929

[0186] Purpose:

[0187] This experiment detected the inhibitory effect of the compound of formula (I) on cell proliferation in multiple myeloma cell lines MM.1S and NCI-H929.

[0188] Experimental Materials:

[0189] Cell lines Tumor type Growth characteristics Cultivation methods MM.1S Multiple Myeloma Semi-adherent RPMI-1640 + 10% FBS NCI-H929 Myeloma Suspension RPMI-1640+0.05mM 2-mercaptoethanol+10%FBS

[0190] Culture medium and reagents Manufacturer Part Number RPMI 1640 GIBCO 22400-089 Dulbecco's PBS Hyclone SH30256.01 FBS Hyclone SY30087.03 Antibiotic-antimycotic GIBCO 15240-062 0.25%Trypsin GIBCO 25200072 DMSO SIGMA D2650 2-mercaptoethanol SIGMA 60-24-2

[0191] 3. Multi-well plate

[0192] Greiner 96-well plate, flat black plate (with lid and clear bottom), #655090.

[0193] 4. Reagents and instruments used in cell viability experiments

[0194] (1) Promega CellTiter-Glo luminescent cell viability assay kit (Promega-G7573).

[0195] (2)2104 En Plate reader, PerkinElmer.

[0196] Experimental protocol:

[0197] 1. Cell Culture

[0198] The tumor cell lines were cultured in an incubator at 37°C and 5% CO2 according to the above culture conditions. Cells in the logarithmic growth phase were subcultured regularly and used for plating.

[0199] 2. Cell Plating

[0200] (1) Stain cells with trypan blue and count live cells.

[0201] Cell line Density (per 96-well) MM.1S 4000 NCI-H929 6000

[0202] (3) Add 90 μL of cell suspension to each well of the culture plate as shown in the table above, and add culture medium without cells to the blank control well.

[0203] (4) Incubate the culture plate in an incubator at 37°C, 5% CO2, and 100% relative humidity overnight.

[0204] 3. Compound Storage Plate Preparation

[0205] Prepare a stock plate with a concentration of 400 times the initial concentration of the compound of formula (I): dilute the compound of formula (I) with DMSO from the highest concentration to the lowest concentration. Prepare it fresh each time.

[0206] 4. Preparation of a working solution with a concentration 10 times the initial concentration of the compound of formula (I) and treatment of cells with the compound

[0207] (1). Preparation of working solution with a concentration of 10 times the initial concentration of the compound of formula (I): Add 76 μL of cell culture medium to a 96-well plate with a V-shaped bottom, and draw 4 μL of the compound from a stock solution storage plate with a concentration of 200 times the initial concentration of the compound of formula (I) and add it to the cell culture medium in the 96-well plate. Add 4 μL of DMSO to the vehicle control and blank control. After adding the compound of formula (I) or DMSO, blow and mix with a dispenser. Add 78 μL of cell culture medium to a 96-well plate with a V-shaped bottom, and draw 2 μL of the compound of formula (I) from a stock solution storage plate with a concentration of 400 times the initial concentration of the compound of formula (I) and add it to the cell culture medium in the 96-well plate. Add 2 μL of DMSO to the vehicle control and blank control. After adding the compound of formula (I) or DMSO, blow and mix with a dispenser.

[0208] (2) Adding drugs: Take 10 μL of the working solution of the compound of formula (I) at a concentration 10 times the initial concentration and add it to the cell culture plate. Add 10 μL of DMSO-cell culture medium mixture to the solvent control and blank control.

[0209] (3) The 96-well cell plate was returned to the incubator to culture MM.1S (3-fold dilution, incubated for 5 days with drug) and NCI-H929 (3-fold dilution, incubated for 5 days with compound of formula (I)).

[0210] 5. CellTiter-Glo luminescence cell activity detection

[0211] The following steps were performed according to the instructions of the Promega CellTiter-Glo Luminescent Cell Activity Assay Kit (Promega-G7573).

[0212] (1) Thaw CellTiter-Glo buffer and allow to cool to room temperature.

[0213] (2) Allow CellTiter-Glo Substrate to cool to room temperature.

[0214] (3) Prepare CellTiter-Glo working solution by adding 10 mL of CellTiter-Glo buffer to a bottle of CellTiter-Glo substrate to dissolve the substrate.

[0215] (4) Slowly vortex to fully dissolve.

[0216] (5) Take out the cell culture plate and let it stand for 30 minutes to equilibrate to room temperature.

[0217] (6) Add 50 μL (equal to half the volume of the cell culture medium in each well) of CellTiter-Glo working solution to each well. Wrap the cell plate with aluminum foil to avoid light.

[0218] (7) Shake the culture plate on an orbital shaker for 2 minutes to induce cell lysis.

[0219] (8) Place the culture plate at room temperature for 10 minutes to stabilize the luminescent signal.

[0220] (9) Detect luminescent signal on 2104 En Vision plate reader.

[0221] 6. Data Analysis

[0222] The inhibition rate (IR) of the compound of formula (I) was calculated using the following formula: IR (%) = (RLU solvent control - RLU compound) / (RLU solvent control - RLU blank control) * 100%. The inhibition rates of the compound of formula (I) at different concentrations were calculated in Excel, and then the inhibition curves were plotted and related parameters were calculated using GraphPad Prism software, including the minimum inhibition rate, maximum inhibition rate and IC 50 .

[0223] Experimental results:

[0224] The test results are shown in Table 6.

[0225] Compound <![CDATA[MM.1S IC 50 (nM)]]> <![CDATA[NCI-H929 IC 50 (nM)]]> Compound of formula (I) 0.4 0.5

[0226] in conclusion:

[0227] The compound of formula (I) exhibits excellent cell proliferation inhibitory effect in multiple myeloma cell lines MM.1S and NCI-H929.

[0228] Test Example 3: Pharmacokinetic Evaluation in Mice

[0229] Purpose:

[0230] In this study, C57BL male mice were selected as test animals. The LC / MS / MS method was used to quantitatively determine the drug concentration in the plasma of mice at different time points after intravenous injection or oral administration of the test compound to evaluate the pharmacokinetic characteristics of the compound of formula (I) in mice.

[0231] Experimental Materials:

[0232] C57Balb / c (C57) mice (male, 20-30 g, 7-10 weeks old, Beijing Weitonglihua or Shanghai Slake).

[0233] Experimental operation:

[0234] The clear or suspended solution of the compound of formula (I) was injected into C57 mice (fasted overnight) via the tail vein, or administered to C57 mice (fasted overnight) by gavage. Blood was collected from the jugular vein by intravenous injection at 0h (before administration) and 0.0833, 0.25, 0.5, 1, 2, 4, 6, 8, 24h after administration, 200μL, placed in an anticoagulant tube (Jiangsu Kangjian Medical Supplies Co., Ltd.) with EDTA-K2 added, and the mixture was vortexed and centrifuged at 13000 rpm for 10 minutes at 4°C; blood was collected from the jugular vein by oral gavage at 0h (before administration) and 0.5, 1, 2, 4, 6, 8, 24h after administration, placed in an anticoagulant tube (Jiangsu Kangjian Medical Supplies Co., Ltd.) with EDTA-K2 added, and the mixture was vortexed and centrifuged at 13000 rpm for 10 minutes. The blood drug concentration was determined by LC-MS / MS, and WinNonlin TM The relevant pharmacokinetic parameters were calculated using the non-compartmental linear logarithmic trapezoidal method using the pharmacokinetic software Version 6.3 (Pharsight, Mountain View, CA).

[0235] Experimental results:

[0236] The test results are shown in Table 7.

[0237] Table 7 Pharmacokinetic parameters of the compound of formula (I) in mice

[0238]

[0239] Test Example 4: Pharmacokinetic Evaluation in Rats

[0240] Purpose:

[0241] In this study, SD male rats were selected as test animals. The LC / MS / MS method was used to quantitatively determine the drug concentration in the plasma of rats at different time points after intravenous injection or oral administration of the compound of formula (I) to evaluate the pharmacokinetic characteristics of the compound of formula (I) in rats.

[0242] Experimental Materials:

[0243] Sprague Dawley (SD) rats (male, 200-300 g, 7-10 weeks old, Beijing Weitonglihua or Shanghai Slake).

[0244] Experimental operation:

[0245] The clear solution of the compound of formula (I) was injected into SD rats via the tail vein (overnight fasting), or administered to SD rats by gavage (overnight fasting). For intravenous administration, 200 μL of blood was collected from the jugular vein puncture at 0 h (before administration) and 0.0833, 0.25, 0.5, 1, 2, 4, 6, 8, 24 h after administration, and placed in an anticoagulant tube (Jiangsu Kangjian Medical Supplies Co., Ltd.) with EDTA-K2 added. The mixture was vortexed and centrifuged at 13,000 rpm for 10 minutes at 4°C; for oral gavage administration, blood was collected from the jugular vein puncture at 0 h (before administration) and 0.5, 1, 2, 4, 6, 8, 24 h after administration, and placed in an anticoagulant tube (Jiangsu Kangjian Medical Supplies Co., Ltd.) with EDTA-K2 added. The mixture was vortexed and centrifuged at 13,000 rpm for 10 minutes. The blood drug concentration was determined by LC-MS / MS, and WinNonlin TM Version 6.3 (Pharsight, Mountain View, CA) pharmacokinetic software was used to calculate relevant pharmacokinetic parameters using the non-compartmental linear logarithmic trapezoidal method.

[0246] Experimental results:

[0247] The test results are shown in Table 8.

[0248] Table 8 Pharmacokinetic parameters of the compound of formula (I) in rats

[0249]

[0250] Test Example 5: In vivo pharmacodynamic study of the compound of formula (I) in a human myeloma MM.1S cell subcutaneous xenograft tumor CB-17SCID model

[0251] Cell culture: Human multiple myeloma cells MM.1S ( CRL-2974 TM ), in vitro semi-suspension culture, culture conditions are ATCC-formμLated RPMI-1640 Medium culture medium with 10% fetal bovine serum, 100U / ml penicillin and 100μg / ml streptomycin, 37℃, 5% CO2 incubator. Process and subculture twice a week. When the cell number reaches the required number, the cells are collected, counted, and inoculated.

[0252] Animals: CB-17 SCID mice, female, 6-8 weeks old, weighing 18-20 g.

[0253] Experimental protocol:

[0254] 0.2 mL (5 × 10 6 MM.1S cells (with Matrigel, volume ratio of 1:1) were subcutaneously inoculated on the right back of each mouse, and the average tumor volume reached 130 mm 3 The administration of the compound of formula (I) was started at 1:00 pm. The administration cycle was seven days, and the compound of formula (I) was orally administered twice a day with an interval of 12 hours each time, for a total of four administration cycles. The dosage of the compound of formula (I) was 5 mg / kg. The tumor volume was measured twice a week with a two-dimensional caliper. The volume was measured in cubic millimeters and calculated by the following formula: V = 0.5a × b 2 , wherein a and b are the long diameter and short diameter of the tumor, respectively. The antitumor efficacy is determined by dividing the mean tumor volume increase of animals treated with the compound of formula (I) by the mean tumor volume increase of untreated animals.

[0255] Experimental results:

[0256] The test results are shown in Table 9.

[0257] Table 9 Test results of the compound of formula (I) in the human myeloma MM.1S cell subcutaneous xenograft tumor CB-17 SCID model

[0258]

[0259] TGI: Tumor Growth Inhibition. TGI (%) = [1-(average tumor volume at the end of drug administration in a treatment group - average tumor volume at the time of drug administration in the treatment group) / (average tumor volume at the end of treatment in the solvent control group - average tumor volume at the beginning of treatment in the solvent control group)] × 100%.

Claims

1. Crystallization of the compound of formula (I) Its X-ray powder diffraction pattern using Cu Kα radiation has diffraction peaks at the following 2θ angles: 10.885±0.200°, 15.303±0.200°, 16.433±0.200°, 18.052±0.200°, 18.942±0.200°, 21.124±0.200°, 21.740±0.200°, 24.417±0.200°, 25.766±0.200°. 0.200°, 26.189±0.200°, 28.741±0.200°, 29.034±0.200°, 31.241±0.200°, 32.588±0.200°, 32.958±0.200°, 33.123±0.200°, 34.985±0.200°, 36.474±0.200° and 37.811±0.200°.

2. The crystal of the compound of formula (I) according to claim 1, whose X-ray powder diffraction pattern using Cu Kα radiation is shown in Figure 1.

3. A method for preparing a crystal of a compound of formula (I) according to claim 1 or 2, comprising: (a) adding the compound of formula (I) into a good solvent to form a solution of the compound of formula (I); (b) slowly adding a poor solvent dropwise under stirring at room temperature; (c) precipitation of solids; The good solvent in step (a) is selected from tetrahydrofuran, and the poor solvent in step (b) is selected from methyl tert-butyl ether.

4. A method for preparing a crystal of a compound of formula (I) according to claim 1 or 2, comprising: (i) adding the compound of formula (I) into an organic solvent and heating to dissolve; (ii) cooling, stirring, and filtering to obtain crystals of the compound of formula (I); The organic solvent is selected from N,N-dimethylformamide.

5. A crystalline composition, wherein the crystals of the compound of formula (I) according to claim 1 or 2 account for more than 50% by weight of the crystalline composition.

6. The crystalline composition of claim 5, wherein the crystals of the compound of formula (I) of claim 1 account for more than 75% by weight of the crystalline composition.

7. The crystalline composition of claim 6, wherein the crystals of the compound of formula (I) of claim 1 account for more than 90% by weight of the crystalline composition.

8. The crystalline composition of claim 7, wherein the crystals of the compound of formula (I) of claim 1 account for more than 95% by weight of the crystalline composition.

9. A pharmaceutical composition comprising a crystal of a compound of formula (I) according to claim 1 or 2 or a crystalline composition according to any one of claims 5 to 8, wherein the pharmaceutical composition comprises at least one pharmaceutically acceptable carrier.

10. The pharmaceutical composition according to claim 9, which is selected from pharmaceutical compositions for oral administration, subcutaneous administration, intramuscular administration or intravenous administration.

11. The pharmaceutical composition according to claim 9 or 10, wherein the pharmaceutical composition is selected from tablets, capsules or granules; or aqueous or non-aqueous solutions for injection.

12. Use of a crystal of the compound of formula (I) according to claim 1 or 2, a crystalline composition according to any one of claims 5 to 8, or a pharmaceutical composition according to any one of claims 9 to 10 in the preparation of a drug for treating a disease associated with the CRBN protein.

13. The use according to claim 12, wherein the disease associated with CRBN protein is selected from multiple myeloma.

Citation Information

Patent Citations

  • Compound based on CRBN ligand inducing EGFR degradation and preparation method thereof, pharmaceutical composition and application

    CN110372669A

  • Novel piperidine-2,6-dione derivative and use thereof

    CN110621664A